Intestinal Perforation: A Rare Complication of Treatment With Bevacizumab

Bevacizumab, a monoclonal immunoglobulin-G1 antibody directed against vascular endothelial growth factor (VEGF), inhibits angiogenesis. Gastrointestinal perforation is a serious and often fatal adverse event related to bevacizumab use. Bevacizumab is indicated in the treatment of colorectal malignan...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikari, Ramesh, Ghose, Medha, Tekin, Aysun, Singh, Simranjit, Singh, Romil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065175/
https://www.ncbi.nlm.nih.gov/pubmed/33907639
http://dx.doi.org/10.7759/cureus.14093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065175/
https://www.ncbi.nlm.nih.gov/pubmed/33907639
http://dx.doi.org/10.7759/cureus.14093

Ejemplares similares